Asset
BEMPIKIBART
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06018428 | phase2 | active_not_recruiting | 2023-09-12 | 2026-06-01 | Q32 Bio Inc. | A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) |
| NCT05509023 | phase2 | active_not_recruiting | 2022-09-30 | 2024-12-01 | Q32 Bio Inc. | Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) |
| NCT04485481 | phase1 | completed | 2020-09-08 | 2022-01-12 | Q32 Bio Inc. | Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers |
FDA applications (0)
This company has no applications containing this asset.